Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.63 |
| ▸ | CTSS | P25774 | 2/20 | 0.63 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.43 |
| ▸ | RELA | Q04206 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576713 | 1.00 | CTSK (0.63) | CTSKCTSSAAK1HDAC4HDAC1 | |
| SCHEMBL19385461 | 1.00 | CTSK (0.63) | CTSKCTSSAAK1HDAC4HDAC1 | |
| SCHEMBL23118362 | 0.99 | CTSK (0.65) | CTSKCTSSAAK1HDAC4HDAC1 | |
| SCHEMBL21427217 | 0.99 | CTSK (0.65) | CTSKCTSSAAK1HDAC4HDAC1 | |
| SCHEMBL21119399 | 0.99 | CTSK (0.65) | CTSKCTSSAAK1HDAC4HDAC1 | |
| SCHEMBL5063217 | 0.99 | CTSK (0.65) | CTSKCTSSAAK1HDAC4HDAC1 | |
| SCHEMBL1424546 | 0.99 | CTSK (0.65) | CTSKCTSSAAK1HDAC4HDAC1 | |
| SCHEMBL29414317 | 0.97 | CTSK (0.60) | CTSKCTSSAAK1HDAC4HDAC1 | |
| SCHEMBL4576559 | 0.95 | CTSS (0.65) | CTSKCTSSAAK1HDAC4HDAC1 | |
| SCHEMBL14151599 | 0.94 | CTSS (0.63) | CTSKCTSSAAK1HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398757-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4380920-A1 | INHIBITORS FOR CORONAVIRUSES | Cocrystal Pharma, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118103351-A | Coronavirus inhibitors | 共晶制药公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023014758-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014758-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-7718611-B2 | Cyclic nonapeptide amides | AICURIS GMBH & CO. KG (DE) | 2010-05-18 | — | — | US | disclosed |
| US-7718611-B2 | Cyclic nonapeptide amides | AICURIS GMBH & CO. KG (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398757-A1 | INHIBITORS FOR CORONAVIRUSES | ACE, ACE2, SARS1 | CTSK 1167/4885CTSS 393/4885AAK1 3750/4885 |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AAAS, PGLS, NRDC | CTSK 682/4885CTSS 339/4885AAK1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.